[Changes resulting from the implementation of the new EU Clinical Trial Regulation 536/2014 from the perspective of patients].

The currently valid Regulation (EU) 536/2014 on clinical trials with medicinal products for human use brings some innovations that are of great importance for patients who participate in clinical trials and patients with a need for innovative therapies. These concern patient protection, especially for vulnerable patient groups, as well as the conditions for further use of data obtained in clinical trials. The introduction of the largely publicly available information system CTIS (Clinical Trials Information System) will significantly improve the transparency of ongoing clinical trials. However, the possibilities of redacting commercially confidential information and postponing the publication of trial-related data and documents for several years may affect the scope of transparency. The request for the sponsor to provide a summary of the protocol and a summary of results of the clinical trial in layman's language (within one year after the end of the trial) also means a massive improvement in transparency for patients, even if this period seems too long, especially for patients with life-threatening diseases. Not all patient-relevant goals originally hoped for have been achieved. The systematic involvement of patients and patient organisations in the clinical trial protocol design is not required by the legislation enacted in 2014. The involvement of patients in the ethical review of the authorisation application dossier is only recommended in the introductory justification, but not codified in the law.
(© 2022. Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature.)